Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

2 weeks ago

WALTHAM, Mass., Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- Invivyd, Inc. ( Nasdaq: IVVD ) , a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced dosing of the first participants in the Phase 1 healthy volunteer clinical trial of VYD2311, ...

Ticker	Sentiment	Impact
IVVD	Neutral	14 %